Novartis inks US-$1.3bn deal with Dunad Th...Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies. more ➔
AstraZeneca unloads respiratory drugs to C...Luxembourg-headquartered Covis is taking two COPD drugs off AstraZenecas hands in a US$270m deal. more ➔
Agomab Therapeutics to acquire Origo Bioph...Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma. more ➔
Evotec goes for massive IPO on NasdaqGerman drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments. more ➔
€40m for Treg starver start-upInstitut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers. more ➔
From make-up to jet fuel: Breakthrough for...The French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach. more ➔
Sofinnova Capital X Fund closed at €472mParis-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe. more ➔
BICO raises €600m and acquires QInstrume...With €600m from a directed share issue in its coffers, BICO finalises the acquisition of QInstruments, a specialist in advanced sample preparation automation. more ➔
European sustainability fund raises €200...The European Circular Bioeconomy Fund, initiated by the EU, has raised more than €200m that will be used to drive the transformation towards a bio-based economy. more ➔
Curevac withdraws MAA of CVnCoVGerman CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine. more ➔
